Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play

Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.

shopping cart
Pfizer is shopping for new clinical-stage assets • Source: Alamy

Pfizer Inc., flush with cash from its COVID-19 vaccine, will buy the clinical-stage immuno-oncology company Trillium Therapeutics Inc. for $2.26bn in an acquisition that will bolster Pfizer's hematology pipeline with two clinical stage compounds targeting a new immune checkpoint, the firms announced 23 August. The acquisition is in line with Pfizer's stated M&A strategy of bringing in mid-stage assets that could drive revenue growth in the 2025-2030 timeframe.

The two lead assets – TTI-622 and TTI-621 – target signal-regulatory protein α (SIRPα -CD47), considered a key immune checkpoint...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.